| Description | Methylprednisolone Acetate(Depo-Medrate) has the ability to inhibit oxygen free radicals and can be used to treat acute spinal cord injuries. |
| In vivo | 典型的股骨头早期无血管性坏死(AVN)特征是由Methylprednisolone Acetate静脉注射（30 mg/kg）结合连续10天每天口服13 mg/kg剂量以及LPS[1]的配合使用引起的。 |
| Synonyms | Depo-Medrate, Depometicort, Depo-Medrin, Depo-medrol, Depomedrone, Lemod |
| molecular weight | 416.51 |
| Molecular formula | C24H32O6 |
| CAS | 53-36-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Soluble |
| References | 1. Luis M Franco,et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med. 2019 Feb 4;216(2):384-406. 2. Ha Thi -Ngan Le, et al. A mouse model of osteonecrotic femoral head induced by methylprednisolone and liposaccharide. Biomedical Research and Therapy volume 3, Article number: 12 (2016) |